<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58723">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938534</url>
  </required_header>
  <id_info>
    <org_study_id>AJOU-EIRB-152692</org_study_id>
    <nct_id>NCT01938534</nct_id>
  </id_info>
  <brief_title>Prospective Study : Helicobacter Pylori Eradication Therapy in Accordance With Past Antibiotics Use</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study : Helicobacter pylori eradication therapy in accordance with past
      antibiotics use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotics resistant is serious problem in helicobacter pylori eradication. Clarithromycin
      is very important antibiotics in eradication. But clarithromycin resistance is increased.
      Major cause of clarithromycin resistance is past consumption of macrolide. Thus the
      investigators propose eradication of macrolide used group bismuth contained four drugs
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori</measure>
    <time_frame>one month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Helicobacter Eradication</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice
for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Helicobacter pylori eradication</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peptic ulcer disease

          -  Gastric MALT lymphoma

          -  Early gastric cancer

          -  Familial history of gastric cancer

          -  Idiopathic iron deficiency

          -  Chronic idiopathic thrombocytopenia

          -  Atrophic gastritis

          -  Helicobacter infected dyspepsia

          -  Long term NSAIDs use

        Exclusion Criteria:

          -  Pregnant

          -  Previous proton pump inhibitor, antibiotics or anticoagulant use within 2 weeks

          -  Previous stomach surgery

          -  Severe ill patients (heart failure, hepatic failure, renal failure, hematologic
             disorder, severe psychologic or neurologic disorder)

          -  Previous Helicobacter eradication

          -  Allergy for Helicobacter eradication medicine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ki Myung Lee, M.D., Ph.D.</last_name>
    <phone>82-31-219-6939</phone>
    <email>lkm5104@ajou.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sun Gyo Lim, M.D.</last_name>
    <phone>82-31-219-6939</phone>
    <email>mdlsk75@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kee Myung Lee, M.D., Ph.D.</last_name>
      <phone>82-31-219-6939</phone>
      <email>lkm5104@ajou.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sun Gyo Lim, M.D.</last_name>
      <phone>82-31-219-6939</phone>
      <email>mdlsk75@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Kee Myung Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 31, 2013</lastchanged_date>
  <firstreceived_date>September 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Sun Gyo Lim</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
